In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 6, 2004, Pages 2007-2013

  Te Dorsthorst, D T A ^a,b   Verweij, P E ^b   Meis, J F G M ^a   Punt, N C ^c   Mouton, J W ^a  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Medimatics   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; BROMIDE; FLUCYTOSINE; ITRACONAZOLE; TETRAZOLIUM;

ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; DRUG ANTAGONISM; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ALGORITHMS; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DRUG INTERACTIONS; FLUCYTOSINE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL;

EID: 2542445436     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.6.2007-2013.2004     Document Type: Article

References (32)

1. Berenbaum, M. C. 1978. A method for testing for synergy with any number of agents. J. Infect. Dis. 137:122-130.
2. Berenbaum, M. C. 1989. What is synergy? Pharmacol. Rev. 41:93-141.
3. Dannaoui, E., E. Borel, F. Persat, M. A. Piens, and S. Picot. 2000. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J. Med. Microbiol. 49:601-606.
4. Dannaoui, E., E. Borel, F. Persat, M. F. Monier, M. A. Piens, et al. 1999. In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. J. Med. Microbiol. 48:1087-1093.
5. Denning, D. W., L. H. Hanson, A. M. Perlman, and D. A. Stevens. 1992. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn. Microbiol. Infect. Dis. 15:21-34.
6. Denning, D. W., K. Venkateswarlu, K. L. Oakley, M. J. Anderson, N. J. Manning, D. A. Stevens, D. W. Warnock, and S. L. Kelly. 1997. Itraconazole resistance inAspergillusfumigatus. Antimicrob. Agents Chemother. 41:1364-1368.
7. Fields, B. T., Jr., W. R. Meredith, J. E. Galbraith, and H. F. Hardin. 1974. Studies with amphotericin B and 5-fluorocytosine in aspergillosis. Clin. Res. 22:32A.
8. Garber, G. 2001. An overview of fungal infections. Drugs 61(Suppl. 1):1-12.
9. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical view from a response surface perspective. Pharmacol. Rev. 47:331-385.
10. Henry, K. W., M. C. Cruz, S. K. Katiyar, and T. D. Edlind. 1999. Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents. Antimicrob. Agents Chemother. 43:1968-1974.
11. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennet, R. E. Green, J.-W. Oestmann, W. V. Kern, K. A. Marr, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
12. Horsburgh, C. R., Jr., S. Feldman, and R. Ridzon. 2000. Practical guidelines for the treatment of tuberculosis. Clin. Infect. Dis. 31:633-639.
13. Hughes, C. E., C. Harris, J. A. Moody, L. R. Peterson, and D. N. Gerding. 1984. In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp. Antimicrob. Agents Chemother. 25:560-562.
14. Kitahara, M., V. K. Seth, G. Medoff, and G. S. Kobayashi. 1976. Activity of amphotericin B, 5-fluorocytosine, and rifampin against six clinical isolates of Aspergillus. Antimicrob. Agents Chemother. 9:915-919.
15. Kontoyiannis, D. P., R. E. Lewis, N. Sagar, G. May, R. A. Prince, and K. V. I. Rolston. 2000. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy. Antimicrob. Agents Chemother. 44:2915-2918.
16. Lauer, B. A., L. B. Reller, and G. P. J. Schröter. 1978. Susceptibility of Aspergillus to 5-fluorocytosine and amphotericin B alone and in combination. J. Antimicrob. Chemother. 4:375-380.
17. Maesaki, S., S. Kohno, M. Kaku, H. Koga, and K. Hara. 1994. Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus. Antimicrob. Agents Chemother. 38:2843-2845.
18. Marr, K. A., T. Patterson, and D. Denning. 2002. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect. Dis. Clin. N. Am. 16:875-894.
19. Meletiadis, J., J. F. G. M. Meis, J. W. Mouton, and P. E. Verweij. 2002. Methodological issues related to antifungal drug interaction modelling for filamentous fungi. Rev. Med. Microbiol. 13:101-117.
20. Meletiadis, J., J. F. G. M. Meis, J. W. Mouton, J. P. Donnelly, and P. E. Verweij. 2000. Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J. Clin. Microbiol. 38:2949-2954.
21. Meletiadis, J., J. W. Mouton, J. F. G. M. Meis, B. A. Bouman, P. J. Donnelly, P. E. Verweij, and EUROFUNG Network. 2001. Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis{2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide}, for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:4256-4263.
22. Moody, J. A. 1992. Synergism testing: broth microdilution checkerboard and broth macrodilution methods, p. 5.18.1-5.18.28. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook. American Society for Microbiology, Washington, D.C.
23. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth microdilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. Nguyen, M. H., F. Barchiesi, D. A. McGough, V. L. Yu, and M. G. Rinaldi. 1995. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob. Agents Chemother. 39:1691-1695.
25. Odds, F. C. 1982. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob. Agents Chemother. 22:763-770.
26. Odds, F. C., F. Van Gerven, A. Espinel-Ingroff, M. S. Bartlett, M. A. Ghannoum, M. V. Lancaster, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, and T. J. Walsh. 1998. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob. Agents Chemother. 42:282-288.
27. Polak, A. 1999. The past, present and future of antimycotic combination therapy. Mycoses 42:355-370.
28. Te Dorsthorst, D. T. A., P. E. Verweij, J. F. G. M. Meis, N. C. Punt, and J. W. Mouton. 2002. Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and - resistant Aspegillus fumigatus isolates. Antimicrob. Agents Chemother. 46:702-707.
29. Vermes, A., H. J. Guchelaar, and J. Dankert. 2000. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 46:171-179.
30. Verweij, P. E., D. T. A. Te Dorsthorst, A. J. M. M. Rijs, H. G. De Vries-Hospers, J. F. G. M. Meis, and the Dutch Interuniversity Working Party for Invasive Mycoses. 2002. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J. Clin. Microbiol 40:2648-2650.
31. Verweij, P. E., K. L. Oakley, J. Morrissey, G. Morrissey, and D. W. Denning. 1998. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 42:873-878.
32. Warris, A., C. M. Weemaes, and P. E. Verweij. 2002. Multidrug resistance in Aspergillus fumigatus. N. Engl. J. Med. 347:2173-2174.